Q32 Bio INC Form 4 insider transactions

Arthur Tzianabos, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Sven Ante Lundberg, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Kathleen Laporte, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Mark T Iwicki, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Diyong Xu, a Director and 10% owner of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Isaac Manke, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

David S. Grayzel, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Mary Thistle, a Director of Q32 Bio Inc., received 10,826 shares of common stock on June 12, 2026.

Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc., received 37,500 shares of common stock on July 16, 2026.

Jodie Pope Morrison, CEO and a Director of Q32 Bio Inc., received 132,000 shares of common stock on July 16, 2026.

Lee Kalowski, CFO and President of Q32 Bio Inc., received 53,250 shares of common stock on July 16, 2026.

Kathleen LaPorte, a Director at Q32 Bio Inc., acquired stock options on June 12, 2026, as detailed in a recent SEC Form 4 filing.

Mark T. Iwicki, a Director at Q32 Bio Inc., acquired stock options for 9,810 shares of common stock.

Isaac Manke, a Director at Q32 Bio Inc., acquired 9,810 stock options with an exercise price of $12.64.

Director Arthur Tzianabos of Q32 Bio Inc. acquired stock options for 9,810 shares.

Director David Grayzel of Q32 Bio Inc. was granted stock options to acquire 9,810 shares of common stock.

Q32 Bio Inc. director Mary Thistle acquired stock options for 9,810 shares of common stock.

Q32 Bio Inc. Director Xu Diyong has been granted stock options, with vesting contingent on continued service and company events.

Sven Ante Lundberg, a Director at Q32 Bio Inc., acquired stock options for 9,810 shares.

Director Diyong Xu acquired 1,875,000 shares of Q32 Bio Inc. common stock through a private placement at $8.00 per share.

OrbiMed Advisors and its affiliated funds acquired 1.875 million shares of Q32 Bio common stock for $15 million in a private placement.

Q32 Bio's Chief Scientific Officer, Shelia M. Violette, was granted 37,500 restricted stock units, vesting over a three-year period.

Q32 Bio Inc.'s CFO and President, Lee Kalowski, was granted 53,250 restricted stock units vesting over three years.

Q32 Bio Inc. CEO and Director Jodie Pope Morrison was granted 132,000 restricted stock units, increasing her beneficial ownership.

Q32 Bio Inc.'s CFO and President, Lee Kalowski, sold 3,995 shares of common stock at a weighted average price of $4.5144 to cover tax withholding obligations.

Q32 Bio Inc.'s CEO, Jodie Pope Morrison, sold 9,896 shares of common stock at a weighted average price of $4.5144 to cover tax withholding obligations related to restricted stock unit vesting.

Q32 Bio's Chief Scientific Officer, Shelia M. Violette, sold 2,815 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Q32 Bio Inc. director Kathleen Laporte was granted 23,272 stock options as part of her compensation, vesting quarterly.

Q32 Bio director David S. Grayzel was granted 16,363 stock options as part of his compensation, vesting quarterly.

Q32 Bio Inc. director Sven Ante Lundberg was granted 20,363 stock options with an exercise price of $3.60, vesting quarterly over one year.